Introduction
A rapid prescreening method for antiviral agents against HIV-1, based on their inhibitory activity in site-directed immunoassays, measuring the binding of antibodies specific for the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp120 to gp120 was described recently (Neurath et al., 1991) . Most (~66%) substances having inhibitory activity in these immunoassays, also inhibited the replication of HIV-1 IIIB, the most commonly used laboratory strain of HIV-1. These substances included 3-amino-fluoranthene, aurintricarboxylic acid (ATA), derivatives of 9-phenyl-6-fluorone (Neurath et al., 1991) and several porphyrin derivatives, including mesotetra (4-carboxyphenyl) porphine (MTCPP; Neurath et al., 1992) , the most potent antiviral compound discerned so far by site-directed immunoassays. The described sitedirected immunoassays relied on recombinant gp120, monoclonal and anti-peptide antibodies corresponding to HIV-1 IIIB and on synthetic peptides from V3100p of other sequenced HIV-1 isolates and the corresponding antipeptide antibodies. However, similar reagents may not be available for the multitude of epidemic HIV-1 strains, the real targets for antiviral chemotherapy. To obviate the need to develop recombinant envelope glycoproteins, monoclonal antibodies and V3 loop peptides for distinct members of five or more HIV-1 families (Sternberg, 1992) , the suitability of more easily obtainable reagents for drug prescreening site-directed immunoassays had to be explored. Human anti-HIV-1 and virions of HIV-1 MN, which is most closely related to primary HIV-I isolates from Europe and North America (Devashet al., 1990; Goudsmit et al., 1990; LaRosa etal., 1990; Zwart et al., 1990; Boudet et al., 1992) have been selected initially to evaluate the feasibility of reagents originating from HIV-1 infected individuals for prescreening immunoassays of antiviral compounds. The sultablllty of human anti-HIV-1 for this purpose was further explored using a synthetic peptide corresponding to a V3 loop consensus sequence (LaRosa et al., 1990) .
Results

Utilization of HIV-1 MN virions and of human anti-HIV-1 in ELISA tests for prescreening compounds for anti-HIV-1 antiviral activity
Among the widely used laboratory strains of HIV-1, the MN strain is most closely related to HIV-1 viruses prevalent in I I infected individuals from Europe and North America (Devash et al., 1990; Goudsmit et el., 1990; LaRosa et al., 1990; Zwart et al., 1990; Boudet et al., 1992) . However, recombinant gp120 from HIV-1 MN has not been available from commercial sources nor from the National Institute of Health AIDS Research and Reference Reagent Program. For this reason, it was decided to USe HIV-1 MN virus concentrates as reagents for developing an ELISA test for prescreening compounds for inhibitory activity on the binding of antibodies to the V3 loop of this virus.
Since the V3 loop represents an immunodominant epltope on gp120, and the level of antibodies recognizing this loop exceeds by more than a factor of 10 the level of antibodies to any other region on gp120 (as measured by immunoassays using synthetic peptides from gp120 IIIB) at least in sera of HIV-1 infected individuals who had not developed symptoms of AIDS (Neurath et al., 1990b; Neurath, 1992) , it was expected that human anti-HIV-1 would be suitable as an antibody reagent for ELISA tests measuring the inhibitory effect of distinct compounds on the reaction between the V3 loop and antibodies specific for this loop. Sera from HIV-1 infected individuals from European and North American countries preferentially recognize the V3 loop of HIV-1 MN and of closely related sequences (Devash et al., 1990; Goudsmit et al., 1990; Zwart et al., 1990; Boudet et al., 1992) .
Before initiating experiments to determine whether or not HIV-1 MN virions and human anti-HIV-1 may represent suitable reagents for immunoassays aiming at prescreening of antiviral compounds directed to the V3 loops of gp120, the inhibitory activity on HIV-1 MN replication of compounds previously shown to have antiviral activity against HIV-1 IIIB (Neurath et al., 1991 (Neurath et al., , 1992 was investigated. As shown in Table 1 , most of the selected compounds inhibited the replication of HIV-1 MN, except ATA, 3-amino fluoranthene, dibenzobicyclo [2,2,2] octane-2-3-dicarboxylic acid, 9-phenyl-2,3,7-tri-hydroxy-6fluorone, 9-phenyl-6-fluorone-2,3,7-tris oxyacetic acid and uroporphyrin III. In addition to compounds already assayed for antiviral activity against HIV-1 IIIB, phtalocyanine tetrasulphonate was also tested. The latter compound had antiviral activity against HIV-1 MN (Table  1) . Earlier results (Neurath et al., 1992) indicated that aluminium phthalocyanine tetrasulphonate did not inhibit the replication of HIV-1 IIIB. These findings are in agreement with the general conclusion that metal chelates of porphyrins have drastically reduced antiviral activity against HIV-1 as compared with metal-free porphyrins (Neurath et al., 1992) .
Next, the suitability of human anti-HIV-1 as a reagent for prescreening of antiviral compounds was assessed by measuring the inhibitory activity of compounds with already established antiviral activity against HIV-1 IIIB on the reaction of these antibodies with a synthetic peptide corresponding to the full-length V3100p of HIV-1 MN. The corresponding results are shown in Fig. 1a . All compounds tested except dibenzobicyclo [2,2,2]octane-2,3dicarboxylic acid inhibited significantly (>20%) the reaction between human anti-HIV-1 and the V3 MN peptide. For comparison, mAb 50.1, directed against the Table 1 . Inhibitory effect of compounds with antiviral activity against HIV-1 IIIB on the replication of HIV-1 MN.
Compounds tested 1 3-aminofluoranthene 2 Dibenzobicylo [2,2,2]octane-2-3-dicarboxylic acid 3 Aurintricarboxylic acid (ATA) 4 s-phenyt-z.a, 7-trihydroxy-6-f1uorone 5 9-phenyl-6-fluorone-2,3,7-tris oxyacetic acid 6 Hemin 7 Chlorin ea 8 Cu-chlorln es 9 Deuteroporphyrin IX, 2,4 (4,2) hydroxyethyl vinyl 10 Deuteroporphyrin IX 2-vinyl 4-hydroxymethyl 11 N-methyl protoporphyrin IX 12 Protoporphyrin IX 13 Meso-tetra (4-carboxyphenyl) porphine ( "EC so = concentration at which the production of p24 was reduced to 50% of that detected in control cultures.
bSI =selectivity index =concentration of the chemical in fLg ml at which 50% of control, uninfected cells were killed divided by ECso• clP = inhibitory activity in all immunoassays described in Figs 1 and 3. In the latter case, results with (1) HIV-1 virions captured on D7324 anti-gp120 antibodies and detected with unadsorbed human anti-HIV-1 and (2) captured on anti-gp41 monoclonal antibodies and detected with human anti-HIV-1 preadsorbad on a peptide corresponding to the immunodominant gp41 epitope, were considered .
. Symbols + and -indicate >20% and <20% inhibition in ELISA tests, considering the least inhibitory results. Numbers in parentheses indicate mean inhibition ± standard deviation. a 20 60 Fig. 1 . Inhibitory effect ofcompounds indicated on the abscissa, shown before to have antiviral activity against HIV·1 IIIB, on the reaction of human anti-HIV-1 and ofmAb 50.1 directed against the V3 loop ofHIV-1 MN, respectively, with afull length V3100p of HIV-1 MN (a), oron the reaction ofhuman anti-HIV-1 and ofrabbit antiserum (diluted 1:40000) to aV3 consensus peptide, respectively, with a full length V3 loop peptide corresponding to aconsensus sequence derived from sequence ofNorth American HIV-1 isolates (LaRosa et a/., 1990) (b). The compounds were tested atafinal concentration of60 fLg ml-1 • The Wells were reacted inthe presence and absence ofthe compounds with the respective polyclonal ormonoclonal antibodies, and the attachment ofIgG was subsequently determined using horseradish peroxidase labelled antihuman, anti-mouse oranti-rabbit IgG. The quantity ofbound IgG inthe absence ofthe compounds corresponded to 00 450 of0. ; V3100p of HIV-1 MN and having virus neutralizing activity against this virus strain, was also used in the assays instead of human anti-HIV-1. Results obtained with these two antibodies were similar, except that 3-amino fluoranthene and 9-phenyl-2,3, 7-tri-hydroxy-f-fluorone also failed to inhibit the binding of mAb 50.1 to the V3 MN peptide. None of the three compounds No.1, 2, and 4 had antiviral activity against HIV-1 MN (Table 1 ). In conclusion, human anti-HIV-1 appears to be a suitable reagent for prescreening of antiviral compounds targeted to the V3 loop, since all the selected substances with proven antiviral activity would have been also discerned using the described ELISA inhibition assays.
To further confirm the suitability of human anti-HIV-1 as reagent for prescreening drugs targeted to the V3 loop of gp120 by ELISA, a peptide corresponding to the full length V3 loop of a consensus sequence for European/North American HIV-1 isolates (LaRosa et al., 1990) was synthesized and used in immunoassays in combination with human anti-HIV-1. The sequence of this peptide differs from the sequence of the V3 loop of HIV-1 MN at six residues (Fig. 2) . Human anti-HIV-1 reacted with the consensus peptide, and the selected compounds, shown before to have antiviral activity against HIV-1 IIIB (Neurath et al., 1991 (Neurath et al., , 1992 , inhibited this reaction (Fig. 1b) . For comparison, similar ELISA inhibition tests were carried out with an antiserum raised against the V3 consensus peptide. In general, the different compounds had a lower inhibitory activity in the latter assay ( Fig. 1b ). Dibenzobicyclo [2,2,2]octane-2,3-dicarboxylic acid, uroporphyrin III, 3-amino fluoranthene, 9-phenyl-2,3,7-tri-hydroxy-6-f1uorone and ATA, all of which failed to inhibit the replication of HIV-1 MN (Table 1) , had the lowest inhibitory activity. Thus, the inhibitory effect of the tested compounds on MN Consensus 1 2 3 4 5 6 7 8 9 IIIII:lltll~J~11~1 2 3 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 6 7 8 9 0 1 2 3 4 5 illi,illil~iiiii,IIII:lilll:'illlllllll~l i l i i 1i l ' i l i l 6 Fig. 2 . Amino acid sequences of gp120 V3 loops from HIV-1 MN and a consensus sequence corresponding to European/North American HIV-1 isolates (LaRosa et a/., 1990) . Common amino acid residues of the two sequences are boxed.
binding of anti-peptide antibodies to the homologous V3 consensus peptide appeared to be the most relevant predictor of antiviral activity against HIV-1 MN. Since synthetic peptides from the V3 loop of epidemic HIV-1 strains belonging to distinct HIV-1 families may not be generally available to develop immunoassays for prescreening antiviral compounds, the suitability of HIV-1 viruses, obtainable by cUlturing infected peripheral blood lymphocytes, as reagents for immunoassays, should be explored. HIV-1 MN was selected as a model system for this purpose. Virus particles were captured on wells of polystyrene plates precoated either with anti-gp41 mAb or with antibodies directed against the C-terminus of gp120. The virus coated wells in combination with human anti-HIV-1 were used in ELISA inhibition tests similar to those described for Fig. 1 . The results of these tests (Fig. 3) indicate that all selected compounds except 3-amino fluoranthene, dibenzobicyclo [2,2,2]octane-2-3-dicarboxylic acid and 9-phenyl~2,3,7-trihydroxy-6-fluorone, compounds lacking antiviral activity against HIV-1 MN (Table  1) , significantly (>20%) inhibited the attachment of human anti-HIV-1 to HIV-1 virions captured by antibodies directed to the C-terminus to gp120. However, the observed inhibitory effects were less, at least with some of the substances, when virions captured on anti-gp41 mAb were used. The reasons for this discrepancy are not known. In order to further address this problem, human anti-HIV-1 was adsorbed on columns of peptide (579-611) from HIV-1 BH10 [the sequence ofthis peptide differs from the corresponding sequence of HIV-1 MN by only two conservative amino acid replacements (Myers et al., 1989) ], encompassing the immunodominant epitope of gp41. Anti-HIV-1, depleted of antibodies to this epitope, was then used as a reagent for ELISA inhibition assays. All selected compounds except dibenzobicyclo [2,2,2] octane-2-3-dicarboxylic acid and ATA, having no inhibitory activity against HIV-1 MN (Table 1) , inhibited the attachment of the adsorbed human anti-HIV-1 to HIV-1 MN virion-coated wells (data not shown).
In summary, results obtained with HIV-1 MN suggest that immunoglobulins prepared from pooled sera from HIV-1-infected individuals selected from a geographical area where infections are caused by a dominant family of HIV-1, and HIV-1 virions corresponding to the same virus family can be used as reagents in immunoassays for prescreening drugs targeted to the V3 loop of gp120. HIV-1 virions for the ELISA tests can be preferentially captured on wells by antibodies directed against the relatively conserved C-terminus of gp120. These antibodies would also capture free gp120 spontaneously released from virus particles Moore et al., 1991; Sattenau and Moore, 1991) gp160 Amino acid residue number {t:it- Fig. 4 . Attachment of meso-tetra (4-carboxyphemyl) porphine (MTCPP) to peptides from gp120/gp41. MTCPP (20 J-Lg rnr ' in TS containing 1 mg rnr' gelatine) was added to peptide coated wells and incubated for 4 h at 20 o G. The wells were washed with TS to remove excess MTCPP, and attached MTCPP was determined by double antibody ELISA using rabbit antiserum to MTCPP (final dilution 1:1000). In control experiments, MTCPP was not added to the peptide-coated wells. The absorbance at 450 nm for the control wells was 0.045-0.114. The ratio of absorbance values corresponding to wells with added MTCPP divided by absorbance corresponding to controls was expressed as ELISA ratio units (ERU) and plotted on the ordinate. The horizontal line at ERU = 2.1 corresponds to the cut-off, distinguishing significant positive from negative results. from infected cells into tissue culture media. Alternatively, human anti-HIV-1 antibodies for these assays can be depleted of antibodies to the immunodominant gp41 epitope by adsorption on immobilized peptides mimicking this epitope, Because of amino acid variability among distinct HIV-1 families of this immunodominant epitope (Neurath, 1993) , peptides with an appropriate sequence would have to be used for this purpose.
The porphyrin derivative meso-tetra (4-carboxyphenyl) porphine (MTCPP)had the highest antiviral activity against both HIV-1 IIIB and MN [(Neurath et al., 1992) ; Table 1 ]. Although MTCPP was shown to inhibit the binding of antibodies to synthetic peptides corresponding to full length V3 loops of several HIV-1 isolates (Neurath et al., 1992) , it has not been established whether or not other sites on gp120 or gp41 would also react with this compound. The successful preparation of antibodies to MTCCP permitted to address this problem by studying the binding of MTCPP to other peptides from gp120 (The peptides available for this purpose were from gp120 corresponding to HIV-1 IIIB [Neurath et al. 1990a] ). MTCPP bound only to the peptide (303-338) corresponding to the V3 loop but not to other peptides from gp120 (Fig. 4) . Marginal binding to the gp41 peptide (771-802) was also observed. Thus, MTCPP appears to be more selective with respect to specificity of binding to the V3 loop in comparison with ATA (Neurath et a/., 1991) .
Discussion
The observation that many primary HIV-1 isolates are resistant to the antiviral effect of soluble CD4, the cell receptor for HIV-1, unlike laboratory strains of the virus (Ashkenazi et al., 1991; Brighty et al., 1991; Moore et a/., 1992; Turner et al., 1992) suggests the importance of including primary HIV-1 isolates belonging to distinct HIV-1 families (Sternberg, 1992) into any investigation concerning antiviral compounds before considering their application for antiviral chemotherapy and designing clinical trials. Such caution is further justified by the observation that several compounds having antiviral activity against HIV-1 IIIB (Neurath et a/., 1991) were inactive against HIV-1 MN (fable 1). Direct testing of many compounds for inhibitory activity against a multitude of primary HIV-1 isolates may be time consuming and prohibitive. However, pre-screening of such compounds by methods simpler than those based on measuring virus replication may enhance the progress in developing anti-HIV-1 drugs with broad specificity. Immunoassays for rapid prescreening of antiviral compounds targeted to the V3 loop of gp120 may be one of the tools to accomplish this goal. Many of the reagents used during our initial studies in this area (Neurath et al., 1991 (Neurath et al., , 1992 , including recombinant proteins, monoclonal antibodies, peptides and antipeptide antisera, are not available for the families of epidemic HIV-1 strains, and cannot easily be prepared. Therefore, the usefulness of simplified immunoassays using reagents derived from cells and from sera of infected individuals for the drug prescreening immunoassays had to be considered.
The observation that the V3 loop of gp120 from several laboratory strains of HIV-1 represented an immunodominant epitope (when tests were carried out with appropriate reagents matching the antigens and antibodies used; Neurath et al., 1990b; Neurath, 1993) offered the possibility of using immunoglobulins from pooled sera of HIV-1-infected individuals as reagents with relative specificity for the V3 loop, since antibodies to other regions of gp120 are present in such preparations at much lower concentrations than antibodies to the V3 loop, and would be diluted out when used as reagents in the immunoassays. The laboratory HIV-1 strain MN, most closely related to primary HIV-1 isolates matched with anti-HIV-1 immunoglobulin prepared from pooled sera of HIV-1infected individuals from the New York and Amsterdam areas (Prince et al., 1988; Devash et al., 1990; Goudsmit et al., 1990; LaRosa et sl., 1990; Zwart et al., 1990; Boudet et al., 1992) was used as the second reagent in developing the immunoassays. The virus particles from crude preparations were captured on wells of polystyrene plates by antibodies specific for the C-terminus of gp120 from HIV-1 IIIB. This region of gp120 is relatively conserved among distinct HIV-1 isolates. Therefore, the capture antibodies are expected to be suitable fo r a muItitude of HIV-1 strains. These antibodies would also capture gp120 in free form either secreted from infected cells or spontaneously shed from the virus. By using such antibodies, it becomes possible to utilize in immunoassays crude virus preparations and tissue culture media containing sufficient quantities of gp120. The suitability of the resulting immunoassays for prescreening of anti-HIV-1 antiviral compounds targeted to V3 loop was confirmed by showing that compounds reported earlier to inhibit the replication of HIV-1 IIIB, most of which also inhibited the replication of HIV-1 MN, inhibited the binding of human anti-HIV IgG to HIV-I MN virions. Thus, all compounds with anti-HIV-1 MN antiviral activity would have been discerned by the prescreening ELISA assays (Table 1) . This suggests that pooled anti-HIV-1 immunoglobulin preparations and HIV-1 viruses collected from the same geographical area may represent a suitable source for reagents for immunoassays intended for prescreening of antiviral compounds targeted to the V3 loop.
Most, if not all, sera from HIV-1-infected individuals also contain high levels of antibodies to an immunodominant epitope of gp41. The presence of these antibodies may hinder the specificity of immunoassays for the V3 loop of gp120. This problem can be minimized by two possible approaches: (1) removal of antibodies specific for this region of gp41 by preadsorption of sera on immobilized synthetic peptides corresponding to this epitope. Since the immunodominant epitope on gp41 is relatively conserved among distinct HIV-1 strains, a single peptide or a series of a few peptides would be sufficient to remove these anti-gp41 antibodies trom anti-HIV-1 sera collected in different areas, (2) the virion preparations could be dissociated with detergents to ensure that only gp120 would be captured on wells of polystyrene plates by antibodies directed against the C~terminus of this envelope glycoprotein. However, the possibility that the V3 loop may not represent the immunodominant gp120 epitope of some HIV-1 isolates cannot be entirely excluded and will have to be considered in developing immunoassays for all HIV-1 families. In this respect, it also appears important to use as a source for anti-HIV-1 immunoglobulins sera from infected individuals before they developed AIDS (Neurath et al., 1990b) . Meso-tetra (4-carboxy-phenyl) porphine (MTCPP) had the highest antiviral activity against both HIV-1 IIiB and MN (Neurath et al., 1991; Fig. 1a ) among all compounds binding to the V3100p of gp120. In order to facilitate future studies on the pharmacodynamics of this compound, anti-MTCPP antibodies were prepared and used to develop an ELISA test. Preliminary studies utilizing this assay indicate that MTCPP is slowly taken up by cells in which HIV-1 replicates (50% uptake in ;:012 h). This suggests the possibility that MTCPP will also bind to the V3100p of gp120 before or during virus assembly and may thus interfere with the production of viable virus. Thus, it seems possible that MTCPP may prevent virus replication not only by binding to extracellular virus but also by rendering already infected cells ineffective in producing virus progeny. This important aspect of the antiviral activity of MTCPP will be further explored.
Materials and Experimental procedures
Enzyme-linked immunoadsorbent assays (ELISA) Wells of 96 well polystyrene plates (Immunlon II, Dynatech Laboratories, Inc., Chantilly, VA) were coated with synthetic peptides corresponding to the V3 loop of HIV-1 MN or to a consensus sequence corresponding to the V3 loop of European/ North American HIV-1 isolates (Fig. 2) as described before (Neurath et al., 1991 (Neurath et al., , 1992 . Subsequently, human anti-HIV-1 IgG (4J-Lg rnl:") (Prince et al., 1988) , mouse mAb 50.1 directed against the V3100p of HIV-1 MN (1.6ng mr ': RepliGen, Cambridge, MA) or rabbit antibodies to the V3 consensus peptide, respectively, were added to the wells. All antibodies were diluted in a mixture of fetal bovine serum and goat serum (9:1) containing 0.1% Tween 20, adjusted to pH 8. All assays were carried out in the presence or absence of compounds shown before to have antiviral activity against HIV-1 IIIB,listed on the abscissa of Fig. 1 (final concentration 60,...g rnl"), The attachment of the respective antibodies to the wells was determined from subsequent attachment of goat antibodies directed against human, mouse or rabbit IgG, each linked to horseradish peroxidase (final dilution of 1:1000) in phosphate-buffered saline (PBS)containing 10% goat serum and 0.1% Tween 20. The enzyme-labelled antibodies were added to the wells for 2 h at 37"C, the wells were washed with PBS and peroxidase activity was determined using a kit from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, MD). Absorbance at 450nm was determined in an MR700 Microplate reader (Dynatech Laboratories, Inc.). The inhibitory effect of the different compounds was determined as described before (Neurath et aI., 1991 (Neurath et aI., , 1992 .
To capture HIV-1 MN virions on wells, the latter were precoated either with mouse monoclonal antibodies (mAb) against gp41 (200ng well:"; catalogue number RV10q020; Olympus Corporation, Lake Success, NY) or with affinity purified sheep antibodies D7324 directed against a 15-amino acid residue peptide from the C-terminus of HIV-1 gp120 (2,...g well": International Enzymes, Inc., Fallbrook, CAl and post-coated with a mixture of bovine serum albumin (BSA) and gelatin (1.0 and 2.5mg rnr', respectively) in 0.14M NaCl, 0.01 MA~s, containing sodium merthiolate (1mg mr '), Five micror~H~s of sucrose density gradient purified HIV-1 MN (1000 x concentrate from Advanced Biotechnologies, Inc., Columbia, MD) diluted with 195,...1 of TS containing 10 mg mr ' of BSA were added to anti-gp41 mAb-and D7324 antibody-coated wells, respectively. The attachment of human anti-HIV-1lgG to HIV-1 virions, in the presence or absence of distinct compounds, was determined as described above except that 0.05% Triton X-100 was added to the reagent for measuring peroxidase activity. The enzymatic reaction was blocked by adding sulphuric acid to a final concentration of 1N. Subsequently, the plates were transferred from a P2 containment facility to the laboratory equipped with a Microplate reader.
Screening of chemicals for antiviral activity
Selected chemicals described before (Neurath et al., 1991 (Neurath et al., , 1992 were screened for antiviral activity against HIV-1 MN by following the inhibition of synthesis of the HIV-1 gag antigen P24 as described before using HIV-1 IIIB (Neurath et al., 1991) . In brief, the chemicals were serially diluted in RPMI-1640 medium without phenol red (Gibco, Grand Island, NY) containing 10% fetal calf serum (FCS). Aliquots of the diluted solutions were added to wells of 96-well plates and mixed with an equal volume of diluted HIV-1 MN [multiplicity of infection (MOl) = 0.0045]. After incubation for 1h at 37"C, 25,...1 of polybrene (1,...g ml-1)-treated MT-2 cells (5000cells well-1 ) were added. The mixture was incubated for 1h at 37"C and the volume was adjusted with RPMI-1640 medium with 10% FCS to 200 J-Li. On the fourth day after incubation at 37"C, 100,...1 of culture supernatants were collected from each well and assayed for p24 using a kit from Coulter Immunology (Hialeah, FL).
Preparation of antiserum to MTCPP MTCPP was linked to ovalbumin using the same procedures as were those described for linking of ATA to BSA (Neurath et al., Anti-HIV-1 antiviral agents selected by immunoassays 213 1991). Rabbits were immunized with the MTCPP-ovalbumin conjugate using the same immunization schedule as described for ATA-BSA Antibodies to MTCPP were detected by double antibody ELISA tests using wells coated with an MTCPP-thyroglobulin conjugate, prepared in the same way as described for the MTCPP-ovalbumin conjugate.
The attachment of MTCPP to peptides from HIV-1 IIIB gp120 was determined similarly as described before for the binding of ATA to these peptides (Neurath et al., 1991) , except that rabbit anti-MTCPP was used instead of anti-ATA
